IP Library Granted Patent US 12,594,351
Granted Patent B2
US 12,594,351 · App. 17/881,092 · Granted Apr 7, 2026

Methods for increasing shelf-life of ophthalmic pharmaceutical compositions

Inventors: Ernesto Fernandez (San Diego, CA); William F. Wiley (Chagrin, OH); Dennis Elias Saadeh (Nashville, TN)
Assignee: Harrow IP LLC
A61L2/04A61K9/0048A61K9/08A61K31/196A61K31/4709A61K31/573A61L2103/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,351
App. No.
17/881,092
Granted
Apr 7, 2026
Kind
B2
Abstract

The present disclosure relates to methods for extending the shelf life of a sterile ophthalmic pharmaceutical composition.

Claims (17)

1 . A method for extending the shelf life of a sterile, preservative-free, ophthalmic pharmaceutical composition, the method comprising:

autoclaving a first phase composition consisting of prednisolone or a pharmaceutically acceptable salt thereof, sodium acetate, sodium chloride polyoxyethylene sorbitan monooleate, hydroxypropyl methylcellulose, optionally hydrochloric acid, optionally sodium hydroxide, and water;

autoclaving or sterile filtering a second phase composition consisting of moxifloxacin, bromfenac, sodium phosphate, sodium metabisulfite, edetate disodium, boric acid, sodium borate, optionally hydrochloric acid, optionally sodium hydroxide, and water; and

combining the first phase composition and the second phase composition, aseptically,

wherein the ophthalmic pharmaceutical composition has a shelf life that is at least 90 days when stored at room temperature.

2 . The method of claim 1 , wherein the autoclaving temperature is about 121° C.

3 . The method of claim 1 , wherein the autoclaving pressure is about 15 psi to about 18 psi.

4 . The method of claim 1 , wherein the first phase composition is autoclaved for about 30 minutes.

5 . The method of claim 1 , wherein the second phase composition is autoclaved for about 30 minutes.

6 . The method of claim 1 , wherein the shelf life of the ophthalmic pharmaceutical composition is at least 120 days when stored at room temperature.

7 . The method of claim 6 , wherein the shelf life of the ophthalmic pharmaceutical composition is at least 180 days when stored at room temperature.

8 . The method of claim 7 , wherein the shelf life of the ophthalmic pharmaceutical composition is at least 240 days when stored at room temperature.

9 . The method of claim 8 , wherein the shelf life of the ophthalmic pharmaceutical composition is at least 270 days when stored at room temperature.

10 . The method of claim 9 , wherein the shelf life of the pharmaceutical composition is at least 300 days when stored at room temperature.

11 . The method of claim 10 , wherein the shelf life of the ophthalmic pharmaceutical composition is at least 365 days when stored at room temperature.

12 . The method of claim 1 , wherein the ophthalmic pharmaceutical composition has a pH of between about 7.5 to about 9.0.

13 . The method of claim 12 , wherein the ophthalmic pharmaceutical composition has a pH of between about 8.3 to about 8.5.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2026
From: FERNANDEZ, ERNESTO; SAADEH, DENNIS ELIAS
To: HARROW IP, LLC
Reel/Frame 073545/0571 →
SECURITY INTEREST Recorded Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556 Recorded Mar 30, 2023
From: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
To: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
Reel/Frame 063205/0889 →
SECURITY INTEREST Recorded Dec 15, 2022
From: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
To: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 062105/0556 →
Continuity (2)
Provisional Application 63229181 · Aug 4, 2021
Related Publication 20230050398A1 · Feb 16, 2023
References Cited (5)
US 20160175317A1 · Shah · 2016 [cited by examiner]
US 20180325854A1 · Coulon · 2018 [cited by examiner]
US 20210369728A1 · Jesudian · 2021 [cited by examiner]
US 20220062301A1 · Shah · 2022 [cited by examiner]
WO 2017192675A1 · 2017 [cited by applicant]